Investigation of the effect of lacosamide on renal function: A 5-Year retrospective cohort study

Basit Öğe Kaydı
dc.authoridAdiguzel, Ahmet/0000-0001-5197-7063
dc.authorwosidAdiguzel, Ahmet/GPG-3954-2022
dc.contributor.authorAdiguzel, Ahmet
dc.date.accessioned2024-08-04T20:59:43Z
dc.date.available2024-08-04T20:59:43Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: Lacosamide, a third-generation antiepileptic drug, is used as adjunctive treatment of partial-onset seizures. It is mainly eliminated through the kidneys. The drug acts by enhancing the slow inactivation of voltage-gated sodium channels. The aim of this study was to investigate the long-term effects of lacosamide on renal function. Material and Methods: The study included two groups of patients with epilepsy (those treated and those not treated with lacosamide) and a healthy control group. Plasma creatinine, blood urea nitrogen, glomerular filtration rate (GFR; by the Modification of Diet in Renal Disease formula), and sodium levels were calculated for the participants at four retrospective time points over 6 years (t0-t1-t2-t3). Results: A total of 123 (female/male=58/65) participants, with a mean age of 33.9 +/- 9.5 years, were included in the study. The study covered a total period of 57.7 +/- 5.5 months. GFRs calculated at all time points for the group receiving lacosamide (GFR0:123.1 mL/min/1.73m2, GFR1:115.1 mL/min/1.73m2, GFR2:112.9 mL/min/1.73m2, and GFR3:102.3 mL/min/1.73m2) were lower than those of the healthy control group (p<0.05). GFR 3 levels was calculated to be lower in patients treated with lacosamide than in patients not treated with lacosamide (p < 0.05).On performing statistical analysis, higher plasma Cr0.2.3 levels were found for the group using lacosamide compared to the healthy control group (p<0.05). Discussion: In this study, all parameters evaluated to investigate the effect of lacosamide on renal functions were found to be within normal ranges in each group. However, plasma GFR levels were found to be lower in the group using lacosamide compared to the control group.en_US
dc.identifier.doi10.4328/ACAM.21059
dc.identifier.endpage15en_US
dc.identifier.issn2667-663X
dc.identifier.startpage11en_US
dc.identifier.urihttps://doi.org/10.4328/ACAM.21059
dc.identifier.urihttps://hdl.handle.net/11616/103482
dc.identifier.volume13en_US
dc.identifier.wosWOS:000769939400003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherBayrakol Medical Publisheren_US
dc.relation.ispartofAnnals of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLacosamideen_US
dc.subjectAntiepileptic Drugsen_US
dc.subjectGFRen_US
dc.subjectSodium Channel Blockeren_US
dc.subjectSeizureen_US
dc.titleInvestigation of the effect of lacosamide on renal function: A 5-Year retrospective cohort studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu